The compound was active at a concentration of 10 nM in reducing the BCR-Abl protein concentration, as well as suppressing the growth of CML cells in vitro even after the drug was removed from the culture. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.